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Abstract
RhoA-mediated cytoskeletal rearrangements in endothelial cells (ECs) play an active role in
leukocyte transendothelial cell migration (TEM), a normal physiological process in which
leukocytes cross the endothelium to enter the underlying tissue. While much has been learned
about RhoA signaling pathways downstream from ICAM-1 in ECs, little is known about the
consequences of the tractional forces that leukocytes generate on ECs as they migrate over the
surface before TEM. We have found that after applying mechanical forces to ICAM-1 clusters,
there is an increase in cellular stiffening and enhanced RhoA signaling compared to ICAM-1
clustering alone. We have identified that the RhoA GEF LARG/ARHGEF12 acts downstream of
clustered ICAM-1 to increase RhoA activity and that this pathway is further enhanced by
mechanical force on ICAM-1. Depletion of LARG decreases leukocyte crawling and inhibits
TEM. This is the first report of endothelial LARG regulating leukocyte behavior and EC stiffening
in response to tractional forces generated by leukocytes.
Introduction
Leukocyte extravasation is a tightly controlled process that involves signaling in both the
leukocyte and endothelial cell (EC). Neutrophils are early responders to sites of infection.
Pro-inflammatory signals prompt them to exit post-capillary venules and infiltrate tissues to
ingest microbes or foreign bodies, destroying them with proteolytic enzymes and/or the
release of reactive oxygen species. In response to inflammatory signals, several adhesion
molecules become expressed or increased on the EC surface including Inter-cellular
adhesion molecule-1 (ICAM-1). Leukocyte transendothelial migration (TEM) starts with
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leukocyte rolling, mediated by leukocyte binding to selectins on the surface of ECs (1). β2
integrins on the leukocyte then bind to ICAM-1 (2–10). The strong adhesion resulting from
ICAM-1 engagement and clustering allows leukocytes to spread and crawl on the surface of
the endothelium. Finally, leukocytes cross the EC monolayer, either passing through the
junctions or through the ECs themselves (9, 11, 12) to enter the underlying tissue. Without
ICAM-1, leukocyte spreading, crawling and TEM are impaired (13, 14).
Engagement and clustering of ICAM-1 by leukocytes induces multiple signaling pathways
within ECs (15) that promote passage of the leukocytes across the endothelium. After
ICAM-1 clustering, F-actin and actin binding proteins associate with the clustered complex
to assist in the cytoskeletal changes that occur during leukocyte adhesion and TEM (16–20).
One of the pathways responsible for these changes involves the GTPase RhoA, which was
shown to be activated following ICAM-1 engagement and clustering (5, 16). Inhibiting
RhoA signaling in ECs reduces leukocyte adhesion, spreading, and migration (3, 4, 13, 21).
RhoA is also activated by various agents, such as thrombin, that increase the permeability of
EC junctions (22–24). In part, this is due to RhoA-stimulated actomyosin contraction that
exerts tension on the junctions, however, there is additional evidence that the adhesive
strength of the junctions is weakened by signaling downstream of active RhoA (25).
Clustering of ICAM-1 also elevates tyrosine phosphorylation of multiple proteins and
several studies have identified Src family kinases (SFKs) as being responsible and being
activated downstream of ICAM-1 (19, 26–28). However, the relationship between SFK
activity and Rho protein activation downstream from ICAM-1 has not been explored.
Cell migration requires the cell to exert tractional forces on the underlying substratum. The
amount of traction force generated by migrating leukocytes has been estimated to be
between 5 and 50 pN (29–31). It is unclear if EC signaling is altered in response to the
tractional force applied by leukocytes to adhesion molecules expressed on the EC luminal
surface. At the outset of this work, we were interested in determining whether the tractional
forces exerted on ICAM-1 as leukocytes migrate affect RhoA signaling, and secondly, we
were interested in identifying the guanine nucleotide exchange factor(s) (GEF) that activate
RhoA downstream of ICAM-1. Here we identify LARG, also known as ARHGEF12, as the
critical RhoA GEF activating RhoA downstream of ICAM-1, show that it is activated by
SFK-dependent tyrosine phosphorylation, and demonstrate that applying mechanical force
on ICAM-1 clusters equivalent to the forces generated by migrating neutrophils enhances
this signaling pathway. We provide evidence that this activation of RhoA not only promotes




RhoA mAb and ICAM-1 mAb (western blotting) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). The mAb against MHC class I (HLA-A, -B, and -C) was
purchased from BD Biosciences (Franklin Lakes, NJ). The pAb for LARG (for
immunoprecipitation) was purchased from Abcam (Cambridge, MA). Phosphotyrosine
mAb, clone 4G10, Y-27632, SU6656, and blebbistatin were purchased from Millipore
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(Billerica, MA). pAb for p115, and phosphorylated myosin light chain (pMLC) (Thr18/
Ser19) were purchased from Cell Signaling (Danvers, MA). pAb for LARG, and PDZ-
RhoGEF were made against the c-terminal tail of the proteins (Pocono Rabbit Farm and
Laboratory, Canadensis, PA). Recombinant TNF and stromal cell–derived factor-1
(CXCL12) was purchased from R&D Systems (Minneapolis, MN). αICAM-1 R6.5.D6
hybridoma was purchased from ATCC (Manassas, VA). mAb for tubulin, mAb for myosin
light chain (MLC), and Cytochalasin D, were purchased from Sigma-Aldrich (St. Louis,
MO). pAb for GEFH1was purchased from Bethyl (Montgomery, TX). mAb myc was
purchased from Invitrogen (Grand Island, NY). Bovine Collagen Solution was purchased
from Advanced BioMatrix (San Diego, CA). Fibronectin was isolated from human plasma
as previously described (32). pAb p190RhoGEF (Rgnef) was a generous gift for Dr. David
D. Schlaepfer (University of California San Diego).
Cell cultures and treatments
Neonatal human dermal blood microvascular ECs (HMVEC), pooled HUVEC, growth
medium and supplements were purchased from Lonza (Walkersville, MD). ECs were
cultured at 37°C and 5% CO2. For all experiments, unless otherwise noted, HMVEC were
grown on 10 μg/ml collagen until confluent for at least 24 h. For all biochemical
experiments at least 104 mAb-coated beads were added per cm2. For all magnetic tweezer
experiments at least 103 beads were added per cm2. Static force was applied by placing a
ceramic magnet above the tissue culture dish for the specified length of time. Primary
human neutrophils were isolated from donor blood drawn by BD Vacutainer ® CPT Cell
Preparation Tubes (BD Biosciences) following the manufacture’s protocol. Briefly, whole
blood was spun for 15 min at 15,000 g. The granulocyte and red blood cell fractions were
recovered and the RBCs lysed. The remaining neutrophils were re-suspended in complete
EC medium containing 1% Human serum albumin and 1 mM HEPES. Institutional Review
Board for University of North Carolina at Chapel Hill has approved all human subject
protocols.
mAb-coated beads and force with the permanent magnet
αICAM-1 R6.5.D6 hybridomas were grown in Cell mAb Serum Free Media (BD
Biosciences) in CELLine CL-1000 Flasks (BD Biosciences) and the Ig was purified from
the hybridoma culture supernatant using a Protein AG UltraLink Resin (Thermo Fisher
Scientific, Waltham, MA). Purified mAb was dialyzed in 0.1 M borate buffer, pH 9.5.
Tosyl-activated Dynabeads M-450 Beads (Invitrogen, Carlsbad, CA) were prepared
following the manufacturer’s protocol. Briefly, beads were washed twice with 0.1 M borate
buffer pH 9.5 and incubated with 1 μg/ml mAb per 106 beads in 0.1 M borate buffer pH 9.5
at 37°C. After 30 min fatty acid-free BSA was added for a final concentration of 0.01% and
rotation continued overnight. For all biochemical experiments, a continuous force (~10 pN)
was applied to mAb-coated beads using a permanent ceramic magnetic (K&J Magnetics,
Jamison, PA) 1 cm above and parallel to the monolayer of ECs in the tissue culture dish.
Magnetic tweezer force assay
mAb-coated beads were added to ECs for approximately 10–20 min and bead tracking was
initiated. Pulses of force (~160 pN) were applied on the beads using the UNC three-
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dimensional force microscope. The magnetic tweezers were positioned ~25 microns above
the monolayer (so as to avoid scraping the underlying monolayer of cells). Force was
applied to individual beads at an acute angle. Cells were imaged using an 40x objective
(Olympus UplanLN 40x/.75) on an Olympus IX81®-ZDC2 inverted microscope (Olympus)
equipped with a high-speed Rolera EM-C2 camera (QImaging) to record bead movement
using MetaMorph software at 30 frames per second. Bead movements above 70 nm were
tracked by Video Spot Tracker (Center for Computer Integrated Systems for Microscopy
and manipulation, http://http://cismm.cs.unc.edu). Before experiments began, the magnetic
tweezer system was calibrated by applying a force ramp to magnetic beads in a Newtonian
fluid of a known viscosity. By recording bead trajectories and computing bead velocities,
Stokes law, F = 6πaηv, was used to determine the force, where a is the bead radius, η is the
fluid viscosity, and v is the bead velocity. Knowledge of the bead displacement r(t) and the
applied force F(t) allowed for computing the compliance signature, J(t) = 6πar(t)/F(t), which
was then fit to a modified Kelvin-Voigt mechanical circuit model for viscoelastic liquids.
The spring constant was reported as the local stiffness in pascals (Pa).
Preparation of recombinant proteins
pGEX GST-PBD and pGEX GST-RhoAG17A fusion proteins were prepared from lysates
from Bl21 Escherichia coli cells induced with 100 μM IPTG for 16 h at RT. For GST-RBD,
bacterial cells were lysed in 20 mM Tris pH 7.8, 1% Triton 100, 10 mM MgCl2 1 mM DTT,
1mM PMSF, and 10 μg/ml aprotinin and leupeptin. For GST-RhoAG17A bacterial cells were
lysed in 20 mM HEPES pH 7.8, 150 mM NaCl, 10 mM MgCl2, 1mM PMSF, and 10 μg/ml
aprotinin and leupeptin. The recombinant proteins were isolated from the bacterial lysates by
incubating with glutathione-Sepharose 4B beads (GE Healthcare) at 4°C for 4 h. The beads
were sedimented and washed 3 times in 20 mM HEPES, pH 7.5; 150 mM NaCl mM DTT.
GST-RBD and GST-RhoAG17A Pull-down Assay
RhoA activation assays were preformed as described (33). HUVECs were lysed in 300 μL of
10 mM MgCl2, 500 mM NaCl, 50 mM Tris, pH 7.8, 1% Triton X-100, 0.1% SDS, 0.5%
deoxycholate, 1mM PMSF, and 10 μg/ml aprotinin and leupeptin, cleared at 14,000g at 4°C
for 3 min and incubated with at least 20 μg of GST-RBD for 20 min at 4°C. Beads were then
washed 3x in 50 mM Tris, pH 7.4, 10 mM MgCl2, 150 mM NaCl, 1% Triton X-100, 1mM
PMSF, and 10 μg/ml aprotinin and leupeptin. Active GEFs were assayed by binding to GST-
RhoAG17A as described (34). In short it was performed as the RhoA activation assays with
the following changes. HUVECs were lysed in 150 mM NaCl, 20 mM HEPES, pH 7.6, 10
mM MgCl2, 1% Triton X-100 1mM PMSF, and 10 μg/ml aprotinin and leupeptin, and
incubated with GST-RhoAG17A beads for 60 min at 4°C and washed in the same lysis
buffer. Samples were then analyzed by western blotting.
Western Blotting
Samples were run on SDS-PAGE gels and transferred to polyvinylidene fluoride membranes
(Millipore). Membranes were blocked and incubated with the specified primary antibodies
followed by species-specific secondary antibodies conjugated with horseradish peroxidase.
Blots were developed with a chemiluminescent HRP substrate, and visualized on x-ray film.
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For quantification, blots were scanned and the intensity values determined using Image J
software (NIH) and protein levels were normalized to control protein levels. All
quantification graphs include ≥3 independent experiments. Error bars represent SEM.
Phase contrast microscopy
HUVECs were grown collagen-coated coverslips for at least 72 h before imaging. HUVECs
were treated with 5 ng/ml TNF overnight. Beads were added for 15 min then unbound beads
were washed off. Cells were fixed with 3.7% paraformaldehyde and mounted on coverslips.
Coverslips were then imaged using a 20x objective (Zeiss plan-Apochromat 20x/0.8) with a
Zeiss axiovert 200 M microscope with a Hamamatsu ORCA-ERAG digital camera and
MetaMorph software.
Immunoprecipitation
HUVECs were lysed on ice for 30 min in lysis buffer (10 mM Tris, pH 7.4, 150 mM NaCl,
1% Triton X-100, 0.5% NP-40, containing 1mM PMSF, and 10 μg/ml aprotinin and
leupeptin, and 10 μg/ml orthovanadate). Lysates were precleared with protein A/G-agarose
beads, and then incubated with LARG pAb overnight at 4 °C. A/G-agarose beads added for
1 h at 4 °C, then were sedimented and washed in lysis buffer at 4°C, resuspended in sample
buffer, boiled for 10 min, and analyzed by Western blotting.
Viral shRNA Knockdown of protein expression
The targeted sequence for LARG was GCGAGTATCCAGAGAAGGAAT and prepared by
the UNC lenti-shRNA core. ECs were grown to 80% confluency and infected with the
lowest amount of viral particles to ensure sufficient knockdown (KD) at 48 h. Infected cells
were then selected with 2.5 μg/ml puromycin for 24 h. For biochemical experiments, ECs
were allowed to grow until confluent. For imaging experiments ECs were re-plated at
confluence. RhoA knockdown re-expression was achieved using adenovirus miRNA and
WT RhoA re-expression as previously described (35). After KD and RhoA rescue, cells
were re-plated at a high density for experimental assays.
Electrical impedance measurement of monolayer integrity
After puromycin selection, high density HMVECs were plated on SIM plates (Roche
Applied Science) coated with 6 μg/ml collagen. Electrical impedance was measured using
the xCELLigence Real-Time Cell Analyzer (RTCA) system (Roche Applied Science). Each
experiment was performed in triplicate and repeated 3 times.
Live-cell imaging
HMVECs were grown on collagen-coated glass dishes (MatTek Corporation) for at least 72
h before imaging. HMVECs were treated with 5 ng/ml TNF overnight. Neutrophils were
added for 10 min then unbound cells were washed off. Cells were then imaged at 37°C and
5% CO2 using a 20x objective (Zeiss plan-Apochromat 20x/0.8) with a Zeiss axiovert 200
M microscope with a Hamamatsu ORCA-ERAG digital camera and MetaMorph software
for 30 min in EC growth medium. A manual tracking plug-in (http://rsbweb.nih.gov/ij/
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plugins/track/track.html) for Image J software (NIH) was used to determine cell migration
velocities.
TEM assay
TEM assays were performed in transwell plates (Corning, Corning, New York, U.S.) of 6.5-
mm diameter with 8-μm pore filters. HMVECs were plated to generate a confluent
monolayer on collagen-coated transwell filters and treated with 5 ng/ml TNF overnight.
Neutrophils were added to the upper chamber and allowed to migrate across the monolayer
to 25 ng/ml CXCL12 for 1 h at 37°C and 5% CO2. The filters were fixed, stained with DAPI
and neutrophils that had migrated to the lower chamber were counted by fluorescence
microscopy using a 20x objective (Zeiss plan-Apochromat 20x/0.8) with a Zeiss axiovert
200 M microscope with a Hamamatsu ORCA-ERAG digital camera and MetaMorph
software. The experiment was preformed four times in duplicate.
Statistical analysis
Statistical significance of data was determined using a two-tailed unpaired t test.
Results
Mechanical force on ICAM-1 increases cellular stiffness around ICAM-1 clusters
We first sought to determine if mechanical force on ICAM-1 induces a cellular response.
We used beads coated with αICAM-1 mAb as a model to mimic leukocyte-induced ICAM-1
clustering (12). The beads were also magnetic, allowing us to apply force on the ICAM-1
clusters. To assess cellular stiffness, we measured displacement of attached beads during
pulses of force (36–38). We applied pulses of 160 pN force on ICAM-1 and tracked the bead
location during each pull (Fig. 1A). There was no statistically significant difference in the
initial average displacements of the beads on cells grown on collagen (0.5 μm) or fibronectin
(0.4 μm). We observed that after the first pulse of force subsequent pulses did not displace
the beads as much, indicating cellular stiffening (Fig. 1B). This stiffening response occurred
whether the ECs had been cultured on a fibronectin or collagen ECM, revealing that the
response was not affected by the integrins through which the ECs were adhering to the
matrix (Fig. 1B,C). Since there was little change in bead displacement between the second
pulse and subsequent pulses, for most experiments we have compared the bead displacement
generated by the first and second pulse.
To explore the basis for the force-induced stiffening, we examined the effects of agents that
perturb the cytoskeleton. The average initial bead displacement for control cells, and cells
treated with blebbistatin, cytochalasin D, Y-27632 and SU6656 were 0.4, 0.6, 0.8, 0.4, and
0.6 μm, respectively. The stiffening response was blocked by disrupting the actin
cytoskeleton with cytochalasin D or by inhibiting myosin activity with blebbistatin (Fig.
1D). To inhibit the RhoA/ROCK pathway we used the ROCK inhibitor Y-27632 (Fig. 1D)
and used adenoviral delivery of miRNA to KD RhoA expression (Fig. 1E, F). We found that
KD of RhoA as well as inhibition of ROCK both inhibited the force-induced stiffening
response. The SFK inhibitor, SU6656, also was able to prevent any change in bead
displacement between pulses (Fig. 1D). Taken together these results suggest that ECs
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respond to mechanical force on ICAM-1 and the observed stiffening response is dependent
on the actin cytoskeleton, myosin activity, RhoA signaling and SFK activity.
RhoA is activated by mechanical force on ICAM-1
After we had determined that the cellular stiffening was dependent on RhoA expression and
actomyosin contractility we next wanted to examine RhoA activity levels. A considerable
body of work has revealed the importance of RhoA within ECs in facilitating the passage of
leukocytes across the endothelium (4, 5, 14, 16). To cluster ICAM-1, we incubated cells for
15 min with magnetic beads coated with αICAM-1 mAb, and then applied force with a
permanent magnet placed above the cell culture dish for 1 min to provide ~10 pN of force
(Fig. 2A). Consistent with previous findings (3, 4, 16), ICAM-1 clustering increased RhoA
activity over untreated cells (Fig. 2A). RhoA activity was further increased within 1 min of
mechanical force on the ICAM-1 bead clusters (Fig. 2A). To evaluate if the observed
activation of RhoA was specific to ICAM-1, we clustered and applied force on MHC class I.
Neither clustering, nor force application on MHC class I significantly affected RhoA activity
(Fig. 2B), confirming that the activation of RhoA is not a universal response to tension on
the cell surface. Both MHC class I beads and the ICAM-1 mAb coated beads were able to
bind to the EC monolayer as seen by phase contrast microscopy (Fig. 2C). MLC
phosphorylation is frequently elevated downstream from RhoA activation and this was
observed paralleling the increase in RhoA activity as ICAM-1 was clustered and then
subjected to force (Fig. 2D).
ICAM-1 signaling activates LARG
While a downstream role for RhoA activity after ICAM-1 engagement has long been
established, the GEF mediating activation of RhoA has not been determined. Using the
binding of GEFs to nucleotide-free mutant RhoAG17A as an indicator of GEF activation
(34), we tested several candidate GEFs including LARG, p190RhoGEF p115RhoGEF, GEF-
H1 and PDZ-RhoGEF, but only observed activation of LARG in response to ICAM-1
clustering (Fig 3A–E). There was an additional increase in LARG activity when force was
applied to the clustered ICAM-1 (Fig. 3A). Neither clustering MHC class I, nor applying
tension on this receptor affected LARG activity (Fig. 3F). ICAM-1 clustering induced
LARG tyrosine phosphorylation and application of force on ICAM-1 further elevated this
phosphorylation (Fig. 3G). Treatment of cells with the SFK inhibitor, SU6656, inhibited
LARG activation induced by ICAM-1 clustering and greatly attenuated LARG activation
after ICAM-1 clustering with force (Fig. 3H). These results strongly suggest a pathway in
which clustering of ICAM-1 activates SFKs (19, 26–28) to phosphorylate and activate
LARG.
Knockdown of LARG expression inhibits RhoA activation downstream of ICAM-1
clustering
To further investigate whether LARG activation is responsible for the increase in RhoA
activity downstream of ICAM-1 signaling, we used lenti-shRNA technology to depress
LARG expression. ECs were infected with LARG shRNA or scrambled control shRNA. We
confirmed by immunoblotting that LARG protein levels were reduced by the lenti-shRNA
treatment and that the levels of similar GEFs like p115 were not decreased (Fig. 4A).
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Interestingly, p115RhoGEF showed a slight increase in expression in response to LARG
knockdown. TNF induction of ICAM-1 expression was preserved with control and LARG
shRNA treatment (Fig. 4B). We also sought to confirm that LARG KD did not alter resting
junctional permeability. This was examined by assaying electrical impedance (Fig. 4C).
After LARG KD there was no RhoA activation in response to ICAM-1 clustering or when
force was applied to the ICAM-1 clusters (Fig. 5A). The control shRNA-treated ECs
exhibited ICAM-1-clustering and force-dependent RhoA activation similar to wild type ECs
(Fig. 5B). To determine if LARG KD affected the cellular stiffness at ICAM-1 clusters, we
used magnetic tweezers as in figure 1. We measured the stiffness of the cells with a single
pulse of force on ICAM-1 (Fig. 5C). The stiffness measured was 50 Pa in control cells
compared to 37 Pa in LARG KD cells. While there was a reproducible trend of ECs
becoming softer after LARG KD, this difference was not statistically significant. However,
after LARG KD there was a loss of the adaptive stiffening at ICAM-1 clusters in response to
force after the first pulse. Compared to the control KD ECs or untreated cells, LARG KD
ECs revealed no change in bead displacement between the first and second pulse (Fig. 5D).
To determine whether ICAM-1-induced stiffening might contribute to increased leukocyte
migration over the EC surface, we disrupted this pathway by knocking down LARG
expression. Neutrophils were plated on a TNF-treated EC monolayers and live cell imaging
was used to calculate the average velocity of neutrophil migration. For neutrophils crawling
on control KD ECs, the average velocity was 3 μm/min, whereas after LARG KD in ECs the
average velocity decreased to 2.5 μm/min (Fig. 5E). Given that leukocytes migrate more
rapidly over stiffer surfaces, these results are consistent with LARG-dependent stiffening of
ECs induced by neutrophil traction enhancing neutrophil migration over the EC surface.
Endothelial LARG contributes to leukocyte TEM
To determine whether endothelial LARG contributes to neutrophil TEM, we counted and
compared the number of neutrophils crossing a control shRNA EC monolayer with the
number crossing a monolayer in which LARG expression had been decreased by shRNA.
The percentage of leukocytes crossing the EC monolayer after LARG KD was decreased by
~35% compared with the control EC monolayer (Fig. 5F). These results show that LARG
activity in ECs promotes both neutrophil migration over the endothelial surface as well as
neutrophil TEM.
Discussion
Leukocyte TEM is an essential step in the recruitment of leukocytes out of the blood
circulation and into tissues during inflammation. In order for TEM to occur, leukocytes must
first adhere to the endothelium and this is mediated by receptors on both the leukocyte and
ECs. ICAM-1 is a key endothelial receptor which functions as a ligand for β2 integrins on
the surface of leukocytes, promoting leukocyte spreading and migration (39). However,
ICAM-1 is more than an adhesive ligand, its engagement and clustering by the leukocyte
generates many signals in ECs that promote TEM (15). It is widely considered that increased
RhoA activity downstream from ICAM-1 clustering (5, 16) contributes to leukocyte TEM
both by weakening the junctions and increasing tension on them to open them (4, 13, 15, 21,
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40, 41). At the outset of this work, we were interested in identifying the GEF(s) responsible
for RhoA activation downstream of ICAM-1, and secondly, we were interested in
determining whether the tractional forces exerted on ICAM-1 as leukocytes migrate affect
RhoA signaling. Here we identify LARG as the critical RhoA GEF activating RhoA
downstream of ICAM-1, show that it is activated by SFK-dependent tyrosine
phosphorylation, and demonstrate that applying mechanical force on ICAM-1 clusters
equivalent to the forces generated by migrating neutrophils enhances this signaling pathway.
This is the first report of RhoA activation downstream of ICAM-1 being regulated by SFKs.
The stiffness of the ECs at ICAM-1 clusters is of great importance as this is where the
leukocyte makes contact with the endothelial cell, exerts tractional force and senses the
endothelial cell stiffness. We provide evidence that this activation of RhoA not only
promotes neutrophil TEM but stiffens the endothelial surface which may enhance the
migration of neutrophils over it.
Our first goal in this work was to identify the GEF(s) downstream from ICAM-1 responsible
for activating RhoA. Several RhoA GEFs have been identified in signaling pathways
initiated by other cell adhesion molecules. For example, in response to integrin-mediated
adhesion on fibronectin, p115 RhoGEF and LARG were found in one study (32) and
p190RhoGEF was implicated in another (42). Tension on fibronectin-based adhesions
further activated RhoA through LARG and GEF-H1 (37). LARG has also been identified in
association with CD44 (43), whereas p114RhoGEF and GEF-H1 have been associated with
tight junctions (44, 45). Together with p115RhoGEF and PDZ-RhoGEF, LARG belongs to
the RGS family of RhoA GEFs, implying that it can be activated downstream of G protein-
coupled receptors via binding to Gα12/13. However, it can also be activated downstream
from integrin engagement as well as following mechanical force on integrins (32, 37). In the
latter case, activation of LARG was induced by tyrosine phosphorylation, either directly or
indirectly by the SFK Fyn (37). Downstream from ICAM-1 clustering and tension on
ICAM-1, we observed that LARG was activated and tyrosine phosphorylated in a time
course that paralleled RhoA activation and that a SFK inhibitor blocked this response. SFKs
not only have been shown to be activated downstream of ICAM-1 signaling (19, 27, 46) but
LARG has also been shown to be a substrate of SFKs (37, 47). KD of LARG expression in
ECs blocked ICAM-1-mediated activation of RhoA, confirming that LARG is critical for
RhoA activation downstream of ICAM-1. We found that p115RhoGEF expression does
increase after LARG KD. This increase in p115RhoGEF expression is not sufficient to
restore RhoA activity downstream of ICAM-1, however it may well be that p115RhoGEF
activity compensates for other signaling pathways in the LARG KD cells. Our results
strongly suggest a pathway in which clustering of ICAM-1 activates SFKs that
phosphorylate and activate LARG. Our results also indicate that mechanical tension on
ICAM-1 clusters enhances this pathway leading to higher levels of LARG tyrosine
phosphorylation, increased activation and elevated levels of GTP-loaded RhoA. These
findings point to LARG as the major regulator of RhoA activity downstream of ICAM-1
signaling.
Previous studies examining endothelial compliance have obtained conflicting results in
response to leukocyte adhesion. Initially, using magnetic twisting cytometry to pull on
integrins, it was found that clustering of ICAM-1 or adhesion of neutrophils to ECs induced
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a stiffening response (48, 49). This is of great interest as it is the region of the cell the
leukocyte would be in contact with and sensing. In contrast, subsequent work by the same
group using atomic force microscopy found transient and localized softening of the
endothelial surface in a zone around where neutrophils adhered but an increased stiffening
of adjacent cells (50). These differences likely result in part from the different techniques
used to measure stiffness, but they may also reflect slight differences in culture conditions
with the former favoring paracellular transmigration (i.e. passage through the junctions) and
the latter favoring transcellular migration (i.e. passage through the EC body). Atomic force
microscopy has also been used to show that treatments, such as TNF, or plating ECs on
stiffer substrata, increase EC stiffness (51, 52). While there have been many studies looking
at the role of EC behavior on substrata of different stiffness (52–56), here we observe that
ECs alter the stiffness of their points of contact with leukocytes in response to tractional
force generated by the leukocyte. The EC response we observe is independent of the type of
ECM protein to which the ECs adhere. In the context of leukocyte migration, stiffer
substrata have been linked to enhanced leukocyte crawling, adhesion and the generation of
stronger tractional forces (30, 31, 57, 58). The finding that mechanical force on ICAM-1
induces a LARG-dependent endothelial stiffening provides a novel mechanism by which
leukocytes can manipulate ECs to facilitate leukocyte TEM.
The recruitment of leukocytes from the blood circulation and into tissues is critical in the
inflammatory response that contributes to defense of the host organism against invasion by
infectious or other foreign agents. However, inappropriate recruitment and activation of
leukocytes underlies many acute or chronic inflammatory diseases. In the search for new
therapeutic targets to combat inflammatory diseases, strategies to inhibit leukocyte TEM
continue to be investigated. Our finding here that inhibiting LARG in ECs decreases TEM,
suggests that LARG may be a suitable anti-inflammatory target that is more specific than
targeting RhoA activity itself which has diverse functions in many cells. Several studies
have recently aimed at developing inhibitors of GEFs including LARG (59, 60), making this
an exciting direction to pursue in the future.
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GEF guanine nucleotide exchange factor
ICAM-1 inter-cellular adhesion molecule-1
HMVEC human microvascular endothelial cells
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MLC myosin light chain
pMLC phosphorylated myosin light chain
SFK src family kinase
TEM transendothelial cell migration
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Mechanical force on ICAM-1 increases cellular stiffening. Magnetic beads coated with
ICAM-1 mAb were added to a monolayer of TNF-treated HMVECs. Magnetic tweezers
were used to apply pulses of force to individual beads and bead movement recorded with
high-speed video. (A) Typical displacement of a bead bound to ICAM-1. Arrows denote
displacement distance (Top). A diagram of the 160 pN force regimen used (3s of force with
5s recovery for 5 pulses) (Lower). Percentage bead displacement in response to sequential
pulses of force for ECs plated on collagen (B) or fibronectin (C). For D–F, the ECs were
plated on collagen. (D) Bead displacements on HMVECs treated with specified inhibitors
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for 30 min followed by 2 pulses of force. (E) Bead displacement on HMVECs and
HMVECs treated with miRNA to inhibit RhoA expression with or without rescue with myc-
RhoA. (F) Western blotting confirms RhoA KD and myc-RhoA re-expression. (B–E)
Quantification of bead displacement with each pulse normalized to the first pulse. Asterisks
shows p-value of statistical significance compared to the control (*, p≤0.05; **, p≤0.01).
The means ± SEM of ≥9 independent bead pulls are shown.
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Mechanical force on ICAM-1 increases RhoA activity and MLC phosphorylation. Magnetic
beads coated with mAb against ICAM-1 (A, C, and D) or MHC class I (B and C) were
added for 15 min to a monolayer of TNF-treated HUVECs and ~10 pN force was applied
with a ceramic magnet placed above the cells for 1 min. (A and B) Using GST-RBD, RhoA.
GTP was isolated and detected by immunoblotting. (C) Phase contrast images of EC
monolayers 15′ after beads were added and washed 2x with media before fixing. (D)
Lysates were immunoblotted for total MLC or MLC phosphorylated on Thr18/Ser19.
Graphs show quantification of RhoA activity (A and B) or pMLC levels (D) from ≥3
independent experiments. Graphs show the means ± SEM. Asterisk shows p-value of
statistical significance compared to control (*, p≤0.05; **, p≤0.01).
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LARG is activated downstream of ICAM-1 clustering alone and enhanced with mechanical
force. TNF-treated HUVECs were treated with mAb-coated beads. (A–F) GEF activity was
determined by affinity purification via GST-RhoAG17A and detected by immunoblotting for
the specified GEF, LARG (A and F), p190RhoGEF (B), p115 (C), GEFH-1 (D), PDZ-
RhoGEF (E). (G) LARG was immunoprecipitated and immunoblotted for phosphotyrosine
and LARG. (H) Active LARG was detected by sedimentation with GST-RhoAG17A in the
presence of SU6656. For all experiments, a representative blot of ≥2 independent
experiments is shown. Graphs show the means ± SEM. Asterisk shows p-value of statistical
significance compared to control by t test (*, p≤0.05; **, p≤0.01).
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Confirmation of LARG KD. HMVECs were treated with control or LARG shRNA lenti-
virus for 48 h and selected for with 2.5 ng/ml puromycin for 24 h. (A) EC lysates were
immunoblotted with the indicated pAb. (B) Western blotting shows that ICAM-1 expression
before and after TNF-treatment is not affected by LARG KD. (C) Electrical impedance was
used to measure monolayer integrity for HMVECs plated at high density for 72 h. No
significant difference was found in impedance values after control or LARG KD. n=3
independent experiments preformed in triplicate wells.
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LARG mediates EC response to mechanical force on ICAM-1 and affects neutrophil
crawling and TEM. HUVECs were treated with control (B and C) or LARG (A and C)
shRNA lenti-virus for 48 h and selected with 2.5 ng/ml puromycin for 24 h, then TNF-
treated overnight. (A and B) RhoA activity was determined by immunoblotting after
ICAM-1 clustering with or without force in HUVECs (left) and quantified (right). The
means ± SEM of ≥4 independent experiments are shown. Asterisk shows p-value of
statistical significance by t test (*, p≤0.05). (C) The stiffness of HMVECs was measured
using magnetic tweezers and magnetic beads coated with ICAM-1 mAb. (D) Relative
displacement of magnetic beads coated with ICAM-1 mAbs was measured in control
HMVECs or in HMVECs in which LARG expression had been knocked down. The means ±
SEM of N≥15 independent bead pulls are shown. Asterisk shows p-value of statistical
significance by t test (p≤0.01). (E and F) Neutrophils were added to a monolayer of TNF-
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treated HMVECs after LARG expression had been knocked down. (E) Neutrophils were
imaged as they migrated over the HMVEC monolayer surface and their velocity was
measured using tracking software. Data are the average of 3 experiments with ≥15
neutrophils measured per experiment. (F) The passage of neutrophils across a confluent EC
monolayer was measured using transwell tissue culture inserts. Data are the average of 3
experiments each performed in duplicate. The means ± SEM are graphed. Asterisk shows p-
value of statistical significance (*, p≤0.05; **, p≤0.01).
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